Immunovaccine's Lead Candidate to Enter Clinical Trial

Immunovaccine (TSX:IMV, OTCQX:IMMVF) announced an investigator-sponsored Phase 2 clinical trial to evaluate the use of a triple-combination immunotherapy in patients with measurable or recurrent diffuse large B-Cell lymphoma (DLBCL).
As quoted in the press release:

Investigators will assess the efficacy and safety of Immunovaccine’s lead candidate, DPX-Survivac, along with a checkpoint inhibitor drug currently marketed by a large pharmaceutical company, and low-dose cyclophosphamide. Immunovaccine expects the trial to begin enrolling patients following receipt of regulatory clearance from Health Canada.
“While immunotherapies, such as checkpoint inhibitors, are rapidly changing the standard of care in many cancers, it has been reported that only about 20 percent of patients are able to respond to these therapies alone, leaving the vast majority of patients with a significant unmet medical need,” said Frederic Ors, Chief Executive Officer at Immunovaccine.ⁱ “Our clinical strategy builds on our earlier research, which indicated that novel combination immunotherapies-particularly those with the ability to increase T-cell tumor infiltration-may work together synergistically to increase the number of patients responding to today’s advanced treatments. We remain committed to working with world-class partners to bring these combinations through clinical development. Our goal is to generate more therapeutic options for patients currently underserved in today’s treatment landscape.”

Click here to read the full press release.